120 related articles for article (PubMed ID: 21498534)
21. Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma.
Sawka AM; Orlov S; Gelberg J; Stork B; Dowar M; Shaytzag M; Tabatabaie V; Freeman JL; Walfish PG
Head Neck; 2008 Jun; 30(6):693-700. PubMed ID: 18098308
[TBL] [Abstract][Full Text] [Related]
22. Treatment of locally aggressive well-differentiated thyroid cancer.
Martins AS; Melo GM; Valério JB; Langner E; Lage HT; Tincani AJ
Int Surg; 2001; 86(4):213-9. PubMed ID: 12056464
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
24. Comparison of efficacy of 2220 MBq versus 3700 MBq I-131 for ablation of thyroid remnant in patients with differentiated thyroid cancer.
Fish SA; Basu S; Alavi A; Mandel SJ
Q J Nucl Med Mol Imaging; 2010 Oct; 54(5):560-3. PubMed ID: 20927023
[TBL] [Abstract][Full Text] [Related]
25. Differentiated thyroid cancer in a Swedish county--long-term results and quality of life.
Malterling RR; Andersson RE; Falkmer S; Falkmer U; Niléhn E; Järhult J
Acta Oncol; 2010 May; 49(4):454-9. PubMed ID: 20092427
[TBL] [Abstract][Full Text] [Related]
26. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
27. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope.
Podnos YD; Smith DD; Wagman LD; Ellenhorn JD
J Surg Oncol; 2007 Jul; 96(1):3-7. PubMed ID: 17567872
[TBL] [Abstract][Full Text] [Related]
28. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality.
Chow SM; Law SC; Chan JK; Au SK; Yau S; Lau WH
Cancer; 2003 Jul; 98(1):31-40. PubMed ID: 12833452
[TBL] [Abstract][Full Text] [Related]
29. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival.
Zidan J; Karen D; Stein M; Rosenblatt E; Basher W; Kuten A
Cancer; 2003 Mar; 97(5):1181-5. PubMed ID: 12599223
[TBL] [Abstract][Full Text] [Related]
30. The role of radioactive iodine therapy in young patients with papillary thyroid cancer.
Kuo SF; Chao TC; Chang HY; Hsueh C; Chang YC; Yang CH; Lin JD
Clin Nucl Med; 2009 Jan; 34(1):4-6. PubMed ID: 19092372
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.
Lang BH; Lo CY; Chan WF; Lam KY; Wan KY
Ann Surg Oncol; 2007 Feb; 14(2):730-8. PubMed ID: 17103065
[TBL] [Abstract][Full Text] [Related]
32. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
33. [Differentiated thyroid carcinoma, 1972-1992. Follow-up, detection of recurrences and prognostic factors].
Obiols G; Simó R; Burgos R; Tresserras R; Galofré P; Masmiquel L; Hernández C; Mesa J
Med Clin (Barc); 1997 Nov; 109(19):738-43. PubMed ID: 9470182
[TBL] [Abstract][Full Text] [Related]
34. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
35. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
36. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan.
Giovanella L; Suriano S; Ceriani L; Verburg FA
Clin Nucl Med; 2011 Feb; 36(2):109-12. PubMed ID: 21220971
[TBL] [Abstract][Full Text] [Related]
37. Differentiated thyroid carcinoma: an analysis of 249 patients undergoing therapy and aftercare at a single institution.
Amin A; Badwey A; El-Fatah S
Clin Nucl Med; 2014 Feb; 39(2):142-6. PubMed ID: 24368533
[TBL] [Abstract][Full Text] [Related]
38. Differentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factors.
Mihailovic J; Stefanovic L; Malesevic M
Cancer Biother Radiopharm; 2007 Apr; 22(2):250-5. PubMed ID: 17600472
[TBL] [Abstract][Full Text] [Related]
39. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients.
Verburg FA; Mäder U; Reiners C; Hänscheid H
J Clin Endocrinol Metab; 2014 Dec; 99(12):4487-96. PubMed ID: 25259907
[TBL] [Abstract][Full Text] [Related]
40. Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy.
Ito Y; Miyauchi A; Ito M; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Kobayashi K; Kihara M; Miya A
Endocr J; 2014; 61(8):821-4. PubMed ID: 24871888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
